- Two key legal developments could soon pave the way for a resumption of trading in shares of Nasdaq-listed Sinovac, ending a nearly three-year suspension.
- Company’s revenue may have risen 80-fold or more since the suspension thanks to sales of its globally accepted CoronaVac Covid-19 vaccine.
- According to the 2020 report, the company’s sales doubled to $510.6 million last year from $246.1 million in 2019, while its net income tripled to $185.2 million from $65.2 million over the same period.
For further details see:
Greatly Transformed Sinovac Set To Reawaken On Wall Street?